These results highlight a superior ability of EREG-blockade to impact ECM-remodeling in IPF tissue compared to TGFβ inhibition and the existing FDA-approved antifibrotic treatment nintedanib. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.